358 related articles for article (PubMed ID: 17692103)
1. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
3. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
5. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.
Tinguely M; Jenni B; Reineke T; Korol D; Kofler A; Rousson V; Dommann-Scherrer C; Maurer R; Moch H; Probst-Hensch NM
Am J Surg Pathol; 2007 May; 31(5):690-6. PubMed ID: 17460451
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
8. Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival.
Leleu X; Genevieve F; Guieze R; Duhamel A; Andrieux J; Berthon C; Godon A; Prat-Lesaffre S; Depil S; Lai JL; Facon T; Zandecki M;
Leuk Res; 2005 Jun; 29(6):665-71. PubMed ID: 15863207
[TBL] [Abstract][Full Text] [Related]
9. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
10. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
Fonseca R; Harrington D; Oken MM; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Blood EA; Rajkumar SV; Kay NE; Van Ness B; Greipp PR
Cancer Res; 2002 Feb; 62(3):715-20. PubMed ID: 11830525
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of PINI index in patients with multiple myeloma.
Dupire S; Wemeau M; Debarri H; Pascal L; Hivert B; Willekens C; Boyle E; Manier S; Béatrice T; Onraed B; Faucompré JL; Hennache B; Dumontet C; Facon T; Leleu X
Eur J Haematol; 2012 Apr; 88(4):306-13. PubMed ID: 22126676
[TBL] [Abstract][Full Text] [Related]
13. Using genomics to identify high-risk myeloma after autologous stem cell transplantation.
Shaughnessy JD; Barlogie B
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):77-80. PubMed ID: 16399589
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System.
Sagaster V; Kaufmann H; Odelga V; Ackermann J; Gisslinger H; Rabitsch W; Zojer N; Ludwig H; Nösslinger T; Zielinski C; Drach J
Eur J Haematol; 2007 Mar; 78(3):227-34. PubMed ID: 17253972
[TBL] [Abstract][Full Text] [Related]
15. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
Kumar S; Rajkumar SV; Greipp PR; Witzig TE
Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
[TBL] [Abstract][Full Text] [Related]
16. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268
[TBL] [Abstract][Full Text] [Related]
17. bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study.
Miguel-García A; Orero T; Matutes E; Carbonell F; Miguel-Sosa A; Linares M; Tarín F; Herrera M; García-Talavera J; Carbonell-Ramón F
Haematologica; 1998 Apr; 83(4):298-304. PubMed ID: 9592978
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
19. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
Mihou D; Katodritou E; Zervas K
Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]